Universal Diagnostic, SA

Based in Spain, Universal Diagnostic, SL specializes in developing innovative blood tests aimed at early cancer detection, improving patient outcomes through advanced diagnostic solutions. Universal Diagnostic, SL, founded in 2012 in Madrid, Spain, focuses on creating blood tests for cancer detection. The company has successfully raised a total of USD 70. 00 mn through its Series B funding round, with the latest investment coming from Quest Diagnostics Incorporated.

The CEO is John Izrael, and the founder is Juan Martinez-Barea. The company has completed 12 deals, with its most recent deal occurring on February 27, 2025. Universal DX develops blood tests designed to detect cancer early, notably its flagship product, Signal-C®, which targets colorectal cancer with a sensitivity of 92% and specificity of 94%. Utilizing multi-omics and machine learning, Universal DX enhances cancer signal detection in blood samples, facilitating early diagnosis through partnerships with diagnostic networks like Quest Diagnostics.

Universal DX generates revenue primarily from its blood tests, especially the Signal-C® product, sold through agreements with healthcare providers and diagnostic networks. The specific pricing details remain undisclosed, but the structure involves B2B transactions aimed at improving cancer screening access. In 2020, the company reported an EBITDA of USD -1,815,979. 40.

Following its recent funding of EUR 20 million from the European Investment Bank in February 2025, Universal Diagnostic plans to support its international expansion and advance a clinical trial in the U. S. for FDA approval and reimbursement. The company aims to launch additional products targeted at early cancer detection and enter new markets to broaden its reach.